市場調查報告書
商品編碼
1245746
坐骨神經痛治療全球市場規模、份額、行業趨勢分析報告(按類型、分銷渠道、藥物類別(非甾體抗炎藥、類固醇、抗抑鬱藥、其他))、區域展望和預測,2022-2028 年Global Sciatica Treatment Market Size, Share & Industry Trends Analysis Report By Type, By Distribution Channel, By Drug Class (Non-Steroidal anti-inflammatory, Steroids, Antidepressants and Others), By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,坐骨神經痛治療的全球市場規模預計將達到 8.104 億美元,預測期內復合年增長率為 3.5%。
製藥公司越來越重視基於微丸技術開發非甾體硬膜外注射劑。 這主要是由於缺乏硬膜外類固醇治療坐骨神經痛的批准。 基於微粒技術,硬膜外注射可以通過將藥物輸送到受傷的神經來減輕疼痛和炎症。 此外,這項最先進的技術有望提高可樂定的安全性和有效性。 因此,使用微丸技術的新醫藥產品將在預測期內進入市場,極大地推動其擴張。
未經治療的坐骨神經痛會導致長期的背部不適。 因此,許多政府和非政府組織已採取具體措施來提高對坐骨神經痛的認識並防止延誤診斷。 此類活動將通過增加對患者狀況和安全治療的了解來促進預測期內的市場擴張。
COVID-19 影響分析
COVID-19 大流行對全球坐骨神經痛藥物市場的擴張產生了負面影響。 醫療保健面臨的主要挑戰之一是 COVID-19 大流行。 隨著美國、中國、日本、印度和德國等主要國家的長期封鎖,COVID-19 大流行的爆發導致部分或所有製造設施關閉。 此外,世界上大多數工業設施都已關閉或停止運營。 這對治療坐骨神經痛的藥物生產產生了一些影響。
市場增長因素
超重或肥胖的患病率增加
肥胖和超重主要是由消耗的卡路裡和消耗的卡路裡之間的能量不平衡引起的。 在全球範圍內,含有大量脂肪和糖分的高熱量食物的攝入量不斷增加,許多職業都是久坐不動的,交通方式在進化,城市化進程在推進,從那時起,缺乏運動的情況在加劇。 特別是,超重的人往往會給他們的胃帶來壓力。 坐骨神經痛最常見的原因之一是超重。 因此,預計坐骨神經痛的發病率會隨著肥胖和超重的增加而增加。 這將鼓勵擴大坐骨神經痛治療藥物的市場。
老化率增加
所有國家都必須克服重大障礙,使其社會和衛生系統做好準備,以便從這一人口變化中受益。 到 2050 年,80% 的老年人將生活在低收入和中等收入國家。 人口老齡化速度比過去快得多。 到 2020 年,60 歲以上的人口將超過 5 歲以下的人口。 從 2015 年到 2050 年,地球上 60 歲以上人口的比例預計將從 12% 增加到 22%。 骨關節炎以及背部和頸部不適是老年人的常見疾病。 隨著年齡的增長,我們往往會同時出現多種症狀。
市場約束
對症狀的認識不足
坐骨神經痛通常被認為是一種常見的腰痛,因為它並不為人所知。 坐骨神經痛通常會自行消退,但它會永久性損傷神經。 坐骨神經痛和背痛都是在做出正確診斷之前經常被誤認為的背痛形式。 混淆源於許多症狀相同的事實。 然而,背痛和坐骨神經痛並不完全是一回事。
輸入 Outlook
按類型劃分,坐骨神經痛治療市場分為急性坐骨神經痛、慢性坐骨神經痛等。 到 2021 年,慢性坐骨神經痛部分在坐骨神經痛治療市場中的收入份額最大。 慢性坐骨神經痛的特點是慢性坐骨神經痛持續8週以上,通常不會自行消失。 慢性坐骨神經痛可能需要非手術或手術治療,具體取決於根本原因。 這種市場擴張可歸因於慢性坐骨神經痛病例的增加、生活方式的改變以及脊柱腫瘤和椎間盤突出病例的增加。
藥物類別展望
按藥物類別,坐骨神經痛藥物市場分為非甾體類抗炎藥、類固醇、抗抑鬱藥等。 到 2021 年,非甾體抗炎藥 (NSAID) 細分市場將在坐骨神經痛治療市場中佔據最高的收入份額。 非甾體類抗炎藥 (NSAID) 是治療坐骨神經痛最常用的藥物之一。 該項目獲得批准,開拓了巨大的市場潛力。 最受歡迎的藥物類別、止痛藥和消炎藥是最有效的藥物。
分銷渠道展望
根據分銷渠道,坐骨神經痛治療市場分為醫院藥房、零售和專業藥房以及在線供應商。 2021 年,醫院藥房部門在坐骨神經痛治療市場中佔據了相當大的收入份額。 預計該類別將在預測期內增長。 醫院治療各種有坐骨神經痛症狀的患者,使他們成為該行業的主導者。 家庭護理是一種在私人家中提供護理以幫助坐骨神經痛患者的醫療服務。
區域展望
它按地區分析了北美、歐洲、亞太地區和 LAMEA 的坐骨神經痛治療市場。 北美地區將引領坐骨神經痛治療市場,到 2021 年將產生最大的收入份額。 許多重要公司的存在,如 Amneal Pharmaceuticals LLC、雅培、強生,以及該地區藥物製劑製造技術的改進是推動市場增長的主要因素。 在同一地區,由於坐骨神經痛的流行、人類生活方式的改變以及老年人口的增加,預計用於治療坐骨神經痛的藥物需求將會增加。
The Global Sciatica Treatment Market size is expected to reach $810.4 Million by 2028, rising at a market growth of 3.5% CAGR during the forecast period.
Sciatica is a disorder in which the sciatic nerve, a sizable nerve that travels down the back, becomes inflamed and painful. Herniated discs (bulging discs between the vertebrae) and piriformis syndrome (a muscle strain in the posterior (rear) area of the hip) are only two of the many potential causes of sciatica. In most cases, sciatica treatments relieve pain and stop future nerve damage. Sciatica may be treated in several ways, such as with physical therapy, anti-inflammatory drugs, acupuncture, and steroids.
Disease problems such as osteoarthritis, spondylolisthesis, muscular spasms, and lumbar spinal stenosis are often to blame for sciatica. All across the globe, these medical disorders are becoming far more common. Therefore, the likelihood of developing sciatica may rise if certain medical conditions are more prevalent. This will increase the utilization of expected and current therapies during the projection period.
Pharmaceutical firms are placing more and more emphasis on creating non-steroidal epidural injections based on micropellet technology. This is due mainly to the fact that no epidural steroids are licensed for sciatica treatment. The epidural injection based on micropellet technology aids in lowering pain and inflammation by enabling targeted drug delivery to the injured nerves. Moreover, this cutting-edge technology is anticipated to improve the safety and effectiveness of clonidine. Therefore, throughout the duration of the projection, new pharmaceuticals created using micropellet technology would hit the market and significantly boost its expansion.
If sciatica is not treated, it may result in lower back discomfort that lasts for a long time. Therefore, numerous governmental and non-governmental groups are starting specific efforts to raise public awareness of the illness and prevent diagnostic delays. These campaigns to increase patient knowledge of the condition and safe treatment alternatives will fuel market expansion during the projected period.
COVID-19 Impact Analysis
The COVID-19 pandemic had a detrimental effect on expanding the world market for sciatica treatments. One of the main problems facing the healthcare sector was the COVID-19 pandemic. Due to the protracted lockdown in important nations, including the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of manufacturing facilities. Also, this has resulted in the majority of industrial facilities throughout the globe closing down or suspending these manufacturing operations. This has some impact on the production of drugs for sciatica as well.
Market Growth Factors
The increasing rate of overweight or obesity prevalence
Obesity and overweight are primarily caused by an imbalance in energy between calories ingested and burned. Worldwide, there has been a rise in the consumption of calorie-dense foods that are rich in fat and sugar, as well as a rise in physical inactivity due to the sedentary nature of many occupations, evolving transportation options, and escalating urbanization. Much pressure is applied when someone is overweight, especially if they like to carry their extra pounds around their midsection. One of the most typical causes of sciatica is being overweight. As a result, it is expected that the incidence of sciatica will increase along with the increased prevalence of obesity or overweight. This would encourage the market for sciatica treatments to expand.
Growing proportion of aging population
To make sure that their social and health systems are ready to benefit from this demographic transformation, all nations must overcome significant obstacles. Eighty percent of senior citizens will reside in low- and middle-income countries by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over 60 than under five-year-olds. The percentage of people over 60 in the globe will increase from 12% to 22% between 2015 and 2050. Osteoarthritis, as well as back and neck discomfort, are common ailments among older people. People are more prone to many conditions at once as they age.
Market Restraining Factors
Lack of awareness regarding condition
Sciatica is often assumed to be regular back pain because not enough people know about it. Even though sciatica usually goes away on its own, it can cause permanent damage to the nerve that it affects. Sciatica and lower back pain are both types of back pain, and they are sometimes mistaken for each other before a correct diagnosis is made. The confusion comes from many of the symptoms being the same. But low back pain and sciatica are not the same things at all.
Type Outlook
Based on type, the sciatica treatment market is segmented into acute sciatica, chronic sciatica and others. The chronic sciatica segment dominated the sciatica treatment market with maximum revenue share in 2021. Chronic sciatica is characterized by chronic sciatic nerve pain that lasts longer than 8 weeks and typically does not go away on its own. Depending on the underlying reason, chronic sciatica may need nonsurgical or surgical treatment. The expansion of this market may be attributed to the rise in chronic sciatica cases, changes in lifestyle, and an increase in spinal tumor and herniated disc instances.
Drug Class Outlook
By drug class, the sciatica treatment market is fragmented into non-steroidal anti-inflammatory drugs, steroids, antidepressants and others. The non-steroidal anti-inflammatory drug (NSAIDs) segment held the highest revenue share in the sciatica treatment market in 2021. To treat sciatica, non-steroidal anti-inflammatory medicines (NSAIDs) are among the most often given drugs. The items are receiving approvals, which is opening up significant market potential. The most popular class of pharmaceuticals, pain relievers, and anti-inflammatory treatments are the most efficient drugs.
Distribution Channel Outlook
On the basis of distribution channel, the sciatica treatment market is bifurcated into hospital pharmacies, retail & specialty pharmacies and online providers. The hospital pharmacies segment covered a considerable revenue share in the sciatica treatment market in 2021. Over the projection period, the category is likely to grow. Hospitals handle a variety of patients who exhibit sciatica symptoms, making them the dominant player in this industry. Homecare is a medical service that provides care inside private residences and helps people with sciatica.
Regional Outlook
Region wise, the sciatica treatment market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the sciatica treatment market by generarting maximum revenue share in 2021. The presence of many significant companies, including Amneal Pharmaceuticals LLC, Abbott, and Johnson & Johnson, as well as improvements in the region's pharmaceutical formulation manufacturing technology, are the key factors driving the growth of the market. The demand for drugs used to treat sciatica is also expected to rise in the area due to the condition's prevalence, changes in human lifestyle, and an increase in the number of older people.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Market Segments covered in the Report:
By Type
By Distribution Channel
By Drug Class
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures